Alnylam Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Alnylam Pharmaceuticals (Cambridge, MA): 4 reconciled FDA prescription therapies, $220.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterCambridge, MA
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2034-01-01
2024 CMS Total Public Spend$220.1M
2024 Medicare Part D Spend$175.2M
2024 Medicaid Spend$44.9M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Alnylam Pharmaceuticals across sibling Meru public-data platforms.